According to population-based registry data (1993–2008) analysis in Japan, the incidence of MDS sharply increased with age, particularly in those over age 70 years. The incidence in 65–69 years was reported to be 3.1 cases/100,000 (men) and 1.1 cases/100,000 (women), in comparison to 85 years in which the rate was 17.7 and 8.9 cases/100,000, respectively. According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Myelodysplastic Syndrome (MDS).
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Myelodysplastic Syndrome Market, historical and forecasted epidemiology, the pipeline insight as well as the Myelodysplastic Syndrome market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Myelodysplastic Syndrome Market Growth Analysis
The Myelodysplastic Syndrome market analysis section of the report helps to build a detailed comprehension of the historic, current, and forecasted Myelodysplastic Syndrome market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives a thorough detail of Myelodysplastic Syndrome market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Myelodysplastic Syndrome Epidemiology Forecast
The Myelodysplastic Syndrome epidemiology section covers insights about historical and current Myelodysplastic Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Myelodysplastic Syndrome Pipeline Analysis
The Myelodysplastic Syndrome Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Myelodysplastic Syndrome market or expected to get launched in the market during the study period. The analysis covers the Myelodysplastic Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Some of the key companies in the Myelodysplastic Syndrome market include:
Astex Pharmaceuticals
Onconova Therapeutics
Celgene
Aprea Therapeutics
Celyad
And many others.
Myelodysplastic Syndrome Therapies covered in the report includes Guadecitabine (SGI-110), Rigosertib, APR-246, CYAD-02, CC-90009, And others.
Source: Myelodysplastic Syndrome Market Growth